Sorry, you need to enable JavaScript to visit this website.
    Pfizer Press releasePartnering release

Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets

HONG KONG – Jan. 14, 2020 – Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico’s machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases.

“Insilico is advancing its latest target identification systems utilizing machine learning, generative biology methods, and synthetic data generation pipelines, and we are pleased to be collaborating with Pfizer on its target identification efforts,” said Alex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine.

“We look forward to working with Insilico as Pfizer continues to explore new technologies that may be able to help us identify targets and biomarkers that could assist in our discovery programs, and potentially lead to breakthrough therapeutics for patients with unmet medical needs,” said Morten Sogaard, Vice President, Target Sciences, Pfizer.

In September 2019, Insilico Medicine announced a $37 million round led by prominent biotechnology and AI investors.

About Insilico Medicine
Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. Recently, Insilico Medicine published some of the results in Nature Biotechnology, and secured $37 million in series B funding. Since its inception, Insilico Medicine raised over $52 million, published over 70 peer-reviewed papers, applied for over 20 patents, and received multiple industry awards. Website http://insilico.com/

Media Contacts
For further information, images or interviews, please contact:
[email protected]

Product Pipeline

Learn about specific ways our research is leading to medicines and vaccines that will benefit patients around the world.

Corporate Fact Sheet

For more than 170 years, Pfizer has worked to make a difference for all who rely on us.

Coronavirus Resources

Learn about SARS-CoV-2, the coronavirus that causes COVID-19, what you can do to stay safe and prevent the spread, and our scientific efforts to help bring an end to the current global health crisis.

Pfizer Logo

Our logo is shorthand for everything Pfizer represents: an image that is instantly identifiable to our colleagues, patients, the external scientific community, and the public.

Executive Leadership

Meet the executive leadership team, our senior-most leadership and decision-making management body who focus on major financial, strategic, and operational decisions for the entire company.